- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07597174
Mobile App vs. In-Person Pelvic Floor Rehabilitation for Urinary Leakage in Adult Women
Randomized Controlled Non-Inferiority Trial Comparing a Mobile Application Based Program With Conventional Rehabilitation for Stress and Mixed Urinary Incontinence in Adult Women
The goal of this clinical trial is to learn if a mobile app-guided pelvic floor rehabilitation program works as well as standard in-person pelvic floor rehabilitation to treat urinary leakage in adult women.
The main question it aims to answer is:
Does the app program improve quality of life related to urinary leakage as much as in-person rehabilitation?
Researchers will compare the app-based program to in-person rehabilitation to see if both lead to similar improvements in quality of life.
Participants will:
Attend one medical visit before starting to confirm they are eligible Attend one in-person training session with a physiotherapist Follow either an app-based or an in-person pelvic floor rehabilitation program for 3 months Complete quality of life questionnaires at the start and at 4 months
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Background
Urinary incontinence (UI) is common in women and undertreated in Portugal. Only 11% of Portuguese women with UI report having completed any rehabilitation program. Conventional pelvic floor rehabilitation requires supervised sessions two to three times per week for at least 3 to 4 months, mostly available only at tertiary hospitals. Mobile app-based programs may improve access, adherence, and convenience. However, no randomized trial has compared an app-based program directly against supervised rehabilitation as an active comparator in the Portuguese population. An important consideration in participant selection is pelvic floor muscle function. Studies show that up to 53% of women with UI cannot contract the pelvic floor correctly without prior in-person training. For this reason, the ability to voluntarily contract the pelvic floor is an inclusion criterion, confirmed at the baseline medical visit.
Study Design
This is a randomized controlled non-inferiority trial with two parallel arms conducted at the Pelvic Floor Rehabilitation Unit of the Physical and Rehabilitation Medicine (PM&R) Department of ULS São João, a tertiary academic hospital in Porto, Portugal.
The Mobile App
The app-based program was developed by the investigators in collaboration with the Information Systems and Technologies Department and the Data Intelligence Department of ULS São João. It was integrated into the existing My São João App, a platform already in use by patients of the hospital. Prior to the trial, a preliminary version was tested over one month with 10 women with prior experience in supervised pelvic floor rehabilitation and with 4 clinicians specialised in pelvic floor rehabilitation. Participants completed a structured questionnaire assessing interface usability, aesthetics, engagement, and functionality, and took part in a discussion of weaknesses and suggestions for improvement. A final version was developed based on this feedback.
Randomization
After baseline assessment, participants are randomized 1:1 into the intervention or control group by a research assistant not involved in the investigation. Allocation uses a computer-generated random sequence implemented through sequentially numbered sealed opaque envelopes, stored in a locked cabinet accessible only to the research assistant. Envelopes are opened immediately before the initial individual session. Participants and health professionals are not blinded to group allocation.
Intervention Group - App-Based Program (12 weeks)
One in-person medical consultation at the start. Participants install the app, are trained on its use, and receive lifestyle and behavioural recommendations tailored to their UI type and baseline assessment results. Three in-person individual physiotherapy sessions at weeks 0, 4, and 8. At each session, participants are trained on the exercises that will be released on the app following that session. App content includes a structured pelvic floor muscle exercise program released in 3 progressive phases, with gradual increases in duration, repetitions, and positions. Participants perform a daily sequence 3 times per day and two 30-minute sessions per week. Programmable reminders allow participants to set exercise times according to their own schedule. Daily app notifications collect feedback on the number of sessions completed and participant satisfaction. One teleconsultation at week 6 to assess adherence, motivation, side effects, and progress. At week 12, participants are notified via the app to begin the maintenance phase: the daily sequence 3 times per day, 3 days per week. One in-person medical consultation at week 16 to assess compliance and outcomes.
Control Group - Supervised Program (12 weeks)
One in-person medical consultation at the start. Participants receive lifestyle and behavioural recommendations tailored to their UI type and baseline assessment results, and a written leaflet with a pelvic floor exercise sequence to perform 3 times per day. One initial in-person individual physiotherapy session, followed by supervised face-to-face group sessions twice per week (30 minutes each), structured in 3 progressive phases matching those of the app program. One in-person medical consultation at week 6 to assess adherence, side effects, and progress. At week 12, participants are instructed to begin the maintenance phase: 3 exercise sets, 3 days per week. One in-person medical consultation at week 16 to reassess compliance and outcomes.
Assessment Schedule
Outcomes are collected by physiatrists specialised in pelvic floor rehabilitation using a digital data collection form at three time points: baseline (week 0), mid-program (week 6), and end of follow-up (week 16).
Sample Size
Sample size was calculated using WinPepi version 11.65, assuming a significance level of 5%, statistical power of 80%, and a 1:1 allocation ratio. Based on a non-inferiority margin of 10.24 points on the King's Health Questionnaire (KHQ), with standard deviations of 10.545 (intervention) and 6.23 (control), 24 participants are required (12 per group). Accounting for an estimated 33% dropout rate, the target sample is 32 participants.
Statistical Analysis
Continuous variables will be described as means with standard deviations, or medians with interquartile ranges, depending on distribution. Categorical variables will be presented as proportions. Between-group comparisons at end of program will use the independent-samples t-test for normally distributed data, or the Mann-Whitney test otherwise. Categorical variables will be compared using the Chi-square or Fisher's exact test as appropriate. A pre-specified subgroup analysis will examine adherence and clinical improvement according to age, primary diagnosis (SUI or MUI), prior treatments, condition severity, quality of life scores, marital status, educational level, profession, smartphone operating system, duration of smartphone ownership, daily hours of use, and prior experience with health-related apps. A subsequent cost-effectiveness analysis is planned.
Ethical Considerations
The study is conducted in accordance with the ethical principles of the 1964 Declaration of Helsinki and its subsequent amendments. Participation is voluntary. Eligible participants are approached at their first consultation and given a participant information sheet and written informed consent form to take home. Signed consent is confirmed at the second appointment, two weeks later. Participants may withdraw at any time without consequence. All data are anonymised prior to analysis and stored securely with password protection. Only the participant's physiatrist has access to medical records. Results will be disseminated at scientific conferences and in peer-reviewed journals.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Susana A Moreira, PMR specialist
- Número de telefone: +351917210578
- E-mail: s.moreira@ulssjoao.min-saude.pt
Locais de estudo
-
-
-
Porto, Portugal, 4200-319
- Recrutamento
- Hospital de Sao Joao
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- age >18 years
- stress urinary incontinence (SUI) or mixed urinary incontinence with predominance of SUI
- more than one urinary incontinence episode for week in the last month
- pelvic floor muscle strength equal or greater than 2 assessed by Oxford Modified Rating Score
Exclusion Criteria:
- indwelling urinary catheter
- active pelvic neoplasia
- pelvic organ prolapse grade greater than or equal to 2
- active urinary tract infection or macroscopic hematuria
- neurogenic dysfunction of the lower urinary tract
- cognitive deficit, osteoarticular, neurological or psychiatric pathologies that prevent the realization of the therapeutic program
- conservative or surgical treatment of UI in the last 12 months
- pregnancy or recent childbirth (< 6 months)
- impossibility of access or illiteracy to technological means (smartphone)
- unavailability to attend the supervised program due to accessibility, schedule or economic reasons
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Hybrid
mobile app based treatment
|
Mobile app based rehabilitation protocol for Stress and Mixed Urinary Incontinence in Adult Women
|
|
Comparador Ativo: conventional
presential
|
Presential rehabilitation program for Stress and Mixed Urinary Incontinence in Adult Women
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
UI-related quality of life
Prazo: At baseline and in16 weeks
|
UI-related quality of life using the Portuguese version of the King´s Health Questionnaire (KHQ).
KHQ is a disease-specific, self-administered questionnaire designed to assess the impact of UI on quality of life in women.
The responses in KHQ have a four point rating system.
The eight subscales ("domains") score between 0 (best) and 100 (worst).
The Symptom Severity scale is scored from 0 (best) to 30 (worst).
Decreases in KHQ domain scores indicate an improvement in quality of life.
The minimally important difference - the smallest change in score that subjects perceive as beneficial - is 3 points for the symptom severity scale and 5 points for all other KHQ domains.
|
At baseline and in16 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
UI severity
Prazo: At baseline and in16 weeks
|
UI severity using: the ICS pad test, the Portuguese versions of the ICIQ-bladder diary, and of the International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF).
The ICS pad test has been standardized by the International Continence Society and implies drinking 500mL of water and performing a protocol of activities during 1 hour.
The total amount of urine leaked is determined by weighing the pad at the end.
A weight difference of 1g is considered as significative.
The ICIQ-bladder diary is a standardised diary that includes records of the number of incontinence episodes.
The ICIQ-UI Short Form is a self-administered questionnaire for evaluating the frequency, severity and impact on quality of life of UI.
It contains 4 items: frequency of urinary incontinence; amount of leakage; overall impact of urinary incontinence; self-diagnostic item.
It is scored from 0 (best) to 21 (worst), considering 2.5 points for a minimal clinically important difference.
|
At baseline and in16 weeks
|
|
Perception of change
Prazo: At baseline and in16 weeks
|
Perception of change by the patient using the Portuguese version of the Patient Global Impression of Change (PGIC) Scale.
The PGIC Scale is is a global index that may be used to rate the response of a condition to a therapy.
It is a transition scale consisting of a single question asking the patient to rate their urinary tract condition now, as compared with how it was prior to beginning treatment on a scale from 1 (Very much better) to 7 (Very much worse).
|
At baseline and in16 weeks
|
|
Sexual function
Prazo: At baseline and in16 weeks
|
Sexual function using the Portuguese version of the Female Sexual Functioning Index (FSFI).
The FSFI is a survey measuring the sexual functioning of women over the previous 30 days in six different domains: desire, arousal, lubrication, orgasm, satisfaction and pain.
Sexual disfunction severity is classified into five categories based on FSFI total scores: severe (2-7.2),
moderate (7.3-14.4),
mild to moderate (14.5-21.6),
mild (21.7-28.1 "cutoff value"), and no sexual disfunction (28.2-36).
|
At baseline and in16 weeks
|
|
Symptoms of depression/anxiety
Prazo: At baseline and in 16 weeks
|
Symptoms of depression/anxiety using the Portuguese version of the Hospital Anxiety & Depression Scale (HADS) questionnaire.
HADS is a fourteen-item scale with seven items each for anxiety and depression subscales.
Scoring for each item ranges from zero to three.
A subscale score >8 denotes anxiety or depression.
|
At baseline and in 16 weeks
|
|
Health related quality of life
Prazo: At baseline and in 16 weeks
|
Health related quality of life, using the Portuguese version of the EuroQol 5-Dimension 5-level (EQ-5D-5L) questionnaire.
The EQ-5D-5L is a brief, generic, health status measure composed of 5 questions with Likert response options (descriptive system) and a visual analog scale (EQ-VAS).
The latter asks patients to rate their own health from 0 to 100 (the worst and best imaginable health, respectively).
The VAS can be used as a quantitative measure of health outcome that reflects the patient's own judgement.
EQ-5D utility values can be used to calculate QALYs, which can then be used in cost-utility analysis.
|
At baseline and in 16 weeks
|
|
Satisfaction and adherence to treatment .
Prazo: At 16 weeks
|
Satisfaction and adherence to treatment using a 9-point Likert scale and the self-reported number of performed sessions registered in the app (intervention group) and reported by the therapist (control group).
|
At 16 weeks
|
|
Participants assessment of the app quality
Prazo: 16 weeks
|
Participants assessment of the app quality using the Portuguese version of the User Mobile App Rating Scale (uMARS).
The uMARS provides 20 items in a total of 5 subscales, 4 objective quality subscales - Engagement, Functionality, Aesthetics and Information Quality - and 1 subjective quality subscale that adds 6 items to measure the impact perceived by users of the evaluated application.
All items are rated on a 5-point scale from "1.
Inadequate" to "5.
Excellent"; there is an option to select "N/A" if the application component is irrelevant.
The quality score is calculated as follows: App Quality Mean Score = (A+B+C+D)/4, where A: Engagement Mean Score; B: Functionality Mean Score; C: Aesthetics Mean Score; D: Information Mean Score.
Questions rated "N/A" are excluded from the mean score calculation.
Total mean score reflects the overall app quality, higher scores indicate a better user experience.
|
16 weeks
|
|
Direct costs of urinary incontinence
Prazo: At baseline and in16 weeks
|
Direct costs of urinary incontinence with an adapted version of the Dowell-Bryant Incontinence Cost Index (DBICI).
The DBICI gives a detailed measure of the direct economic costs of urinary incontinence in ambulatory home-dwelling women, with the construct validity confirmed by the significant correlation with other quantitative measures of incontinence.
By substituting local prices into the test format, the index can be used in different countries.
|
At baseline and in16 weeks
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças Urogenitais Masculinas
- Doenças Urológicas
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Distúrbios da micção
- Sintomas do Trato Urinário Inferior
- Manifestações Urológicas
- Condições Patológicas, Sinais e Sintomas
- Sinais e sintomas
- Incontinencia urinaria
- Incontinência Urinária, Estresse
Outros números de identificação do estudo
- CE-218-2024
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .